利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.031 秒)

    DNA molecules encoding human CLAX proteins and their soluble fusion proteins
    1.
    发明授权
    DNA molecules encoding human CLAX proteins and their soluble fusion proteins 有权
    编码人类CLAX蛋白的DNA分子及其可溶性融合蛋白

    公开(公告)号：US06455683B1

    公开(公告)日：2002-09-24

    申请号：US09531056

    申请日：2000-03-20

    申请人： Guchen Yang ,  Xiaorong Chen ,  Patricia M. Davis ,  Peter A. Kiener

    发明人： Guchen Yang ,  Xiaorong Chen ,  Patricia M. Davis ,  Peter A. Kiener

    IPC分类号： C07H2102

    CPC分类号： C07K14/705 ,  A61K38/00 ,  C07K14/4726 ,  C07K14/7056 ,  C07K2319/00

    摘要： Isolated novel cDNA sequences encoding a human C-type lectin and three homologues are provided. They are referred to herein as “CLAX” (C-type Lectin, Activation Expressed) proteins. The invention also includes methods of using the nucleic acid sequences, polypeptides encoded by the nucleic acid sequences disclosed herein, fusion proteins having all or a portion (e.g., an extracellular region) of the CLAX proteins, antibodies specific for the novel CLAXs, ligands and inhibitors for the novel CLAXs. The genes of CLAX are specifically expressed in lymphoid tissues and activated T lymphocytes but not resting T lymphocytes. The invention concerns the utility in pharmaceutical compositions for the prevention and treatment of infectious, inflammatory and allergic diseases.

    摘要翻译： 提供了编码人C型凝集素和三个同系物的分离的新型cDNA序列。 它们在本文中称为“CLAX”（C型凝集素，激活表达的）蛋白质。 本发明还包括使用核酸序列的方法，由本文公开的核酸序列编码的多肽，具有CLAX蛋白的全部或部分（例如细胞外区域）的融合蛋白，对于新型CLAXs具有特异性的抗体，配体和 新型CLAXs的抑制剂。 CLAX的基因在淋巴组织和活化的T淋巴细胞中特异性表达，但不是休息的T淋巴细胞。 本发明涉及用于预防和治疗感染性，炎性和过敏性疾病的药物组合物中的应用。

    EPHA2 AND HYPERPROLIFERATIVE CELL DISORDERS
    3.
    发明申请
    EPHA2 AND HYPERPROLIFERATIVE CELL DISORDERS 审中-公开
    EPHA2和高增殖性细胞病变

    公开(公告)号：US20090162933A1

    公开(公告)日：2009-06-25

    申请号：US12177722

    申请日：2008-07-22

    申请人： Peter A. Kiener ,  Michael S. Kinch ,  Solomon Langermann ,  Jennifer L. Reed

    发明人： Peter A. Kiener ,  Michael S. Kinch ,  Solomon Langermann ,  Jennifer L. Reed

    IPC分类号： C12N5/02

    CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K16/32

    摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation, in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low Koff rate. In preferred embodiments, agents of the invention are monoclonal antibodies. The invention also provides pharmaceutical compositions comprising one or more EphA2 agonistic agents of the invention either alone or in combination with one or more other agents useful in therapy for non-neoplastic hyperproliferative cell or excessive cell accumulation disorders.

    摘要翻译： 本发明涉及设计用于治疗，管理或预防非肿瘤性过度增殖性细胞或过度细胞累积障碍，特别是涉及上皮细胞或内皮细胞过度增殖的方法和组合物。 在一个实施方案中，本发明的方法包括在EphA2已经被激动的细胞中施用有效量的结合EphA2并增加EphA2胞质尾磷酸化和/或增加EphA2自磷酸化的EphA2激动剂。 在另一个实施方案中，本发明的方法包括施用有效量的一种或多种EphA2激动剂，其结合EphA2并降低EphA2活性（除了自磷酸化）。 在另一个实施方案中，本发明的方法包括施用有效量的一种或多种结合EphA2的EphA2激动剂并减少病理学引起的细胞表型（例如，导致病理的上皮细胞表型或致病性病因的内皮 细胞表型）。 在另一个实施方案中，本发明的方法包括施用有效量的一种或多种EphA2激动剂，其是以非常低的Koff率与EphA2结合的EphA2抗体。 在优选的实施方案中，本发明的试剂是单克隆抗体。 本发明还提供包含本发明的一种或多种EphA2激动剂的药物组合物，其单独或与一种或多种其它可用于治疗非肿瘤性过度增殖性细胞或过度细胞累积障碍的其它药物组合。